胃癌免疫检查点抑制剂作用机制及最新研究进展

doi:10.11904/j.issn.1002-3070.2019.04.016

Abstract

Abstract: The treatment of gastric cancer is limited and the prognosis is poor.Tumor immunotherapy has been an effective new treatment for cancer in addition to surgery,chemotherapy,radiotherapy and targeted therapy because of its remarkable survival benefit.As one of the methods of tumor immunotherapy,immunological checkpoint inhibitors have been approved for the treatment of various tumors,suggesting that the era of gastric cancer immunotherapy has arrived.This article describes the mechanism of action and related research progress of immunological checkpoint inhibitors in immunotherapy.

Key words: Gastric cancer, Immunotherapy, Immunological checkpoint inhibitors

CLC Number:

R735.2

YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors[J]. Journal of Practical Oncology, 2019, 33(4): 371-375.

References

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
3 丁乃清,魏嘉,陈仿军,等.胃癌免疫治疗临床研究进展[J].肿瘤综合治疗电子杂志,2018,4(2):1-5.
4 Abdel-Rahman O,Helbling D,Schmidt J,et al.Treatment-related death in cancer patients treated with immune checkpoint inhibitors:A systematic review and meta-analysis[J].Clinical Oncology,2017,29(4):218-230.
5 苗素平,郭二亮,裴荣,等.miRNA调节免疫检查点在肿瘤治疗中的研究进展[J].实用肿瘤学杂志,2018,32(1):57-62.
6 卢伸,苏丹.免疫检查点阻断用于肿瘤治疗的研究进展[J].实用肿瘤杂志,2016,31(1):19-23.
7 曾玉兰,刘洋洋,梁金燕,等.免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J].实用肿瘤学杂志,2017,31(4):353-358.
8 Chen L,Flies DB.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nature Reviews Immunology,2013,13(4):227-242.
9 王晓静.胃癌的免疫治疗进展[D].石家庄:河北医科大学,2018.
10 Yokosuka T,Takamatsu M,Kobayashi-Imanishi W,et al.Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J].J Exp Med,2012,209(6):1201-1217.
11 Muro K,Chung HC,Shankaran V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012):a multicentre,open-label,phase 1b trial[J].Lancet Oncology,2016,17(6):717-726.
12 Wainberg ZA,Jalal S,Muro K,et al.KEYNOTE-059 Update:Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal(G/GEJ)cancer[J].Ann Oncol,2017,28(suppl5):616-617.
13 Catenacci DV,Wainberg Z,Fuchs CS,et al.KEYNOTE-059 cohort 3:safety efficacy of pembrolizumab monotherapy for first-line treatment of patients(pts)with PD-L1-positive advanced gastric/gastroesophageal(G/GEJ)cancer[J].Ann Oncol,2017,28(suppl3):153.
14 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer[J].JAMA Oncology,2018,4(5):e180013.
15 Shitara K,zgüroˇglu M,Bang YJ,et al.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061):a randomised,open-label,controlled,phase 3 trial[J].The Lancet,2018,392(10142):123-133.
16 Ohtsu A,Tabernero J,Bang YJ,et al.Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction(GEJ)adenocarcinoma:Phase 3 KEYNOTE-061 study[J].J Clin Oncol,2016,34(15):4137.
17 Kang YK,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
18 Janjigian YY,Bendell J,Calvo E,et al.Check Mate-032:phase Ⅰ/Ⅱ open-label study of safety and activity of nivolumab(nivo)alone or with ipilimumab(ipi)in advanced and metastatic(A/M)gastric cancer(GC)[J].J Clin Oncol,2016,34(15):4010.
19 Dung TL,Johanna CB,Emiliano C,et al.Safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer(GC/GEC):results from the CheckMate-032 Study[J].J Clin Oncol,2016,34(suppl 4S):6.
20 Heery CR,O′Sullivancoyne G,Madan RA,et al.Avelumab for metastatic or locally advanced previously treated solid tumours(JAVELIN Solid Tumor):a phase 1a,multicohort,dose-escalation trial[J].Lancet Oncology,2017,18(5):587.
21 Taieb J,Moehler M,Boku N,et al.Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers:Current status and future perspectives[J].Cancer Treatment Reviews,2018,66:104-113.
22 Eric VC,Lucjan W,Keun-Wook L,et al.P-282JAVELIN Gastric 300:Phase 3 trial of avelumab(anti-PD-L1 antibody)+best supportive care(BSC)vs BSC±chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer[J].Ann Oncol,2016,27(suppl 2):82.
23 Segal NH,Hamid O,Hwu W.A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1(PD-L1)antibody MEDI4736:Preliminary data[J].Ann Oncol,2014,25(suppl4):361-372.
24 Bang YJ,Cho JY,Kim YH,et al.Efficacy of sequential ipilimumab monotherapy vs best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer[J].Clin Cancer Res,2017,23(19):5671.
25 Ralph C,Elkord E,Burt DJ,et al.Modulation of lymphocyte regulation for cancer therapy:A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J].Clin Cancer Res,2010,16(5):1662-1672.

[1]	QIN Wen,ZHAO Nannan,HAN Yonghuan,XU Yajun. Expression of ZNF436 in gastric cancer and its effect on the migration and invasion of gastric cancer cells by WNT/β-catenin [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 222-227.
[2]	MENG Hai,DU Guanxiang,ZHU Liling,TANG Qiyun. The expression of WEE1 in gastric cancer and its influence on prognosis of patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 239-243.
[3]	LIU Jiayin,YAN Feihu,ZHANG Yanqiao. Genetic susceptibility of gastric cancer with single nucleotide polymorphisms(SNPs)of apoptotic genes - caspase-3 and caspase-7 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 250-255.
[4]	BAI Yuxian, MA Zhongjuan, SU Yingling, MU Anguo, XIE Rui. Research on methylation of FHIT,hMLH1,p16,RAR-beta,Reprimo and TIMP3 genes in gastric cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 8-13.
[5]	ZHANG Fengchun, JIANG Ying, LIU Zhaonan, YAN Ningning, CUI Hongquan, XU Yingchun. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 34-39.
[6]	ZHANG Bao, ZHENG Zhichao. Research progress in lymph nodes dissection of advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 78-81.
[7]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[8]	YI Qingting, ZHANG Hongjun, JIANG Tao, FU Jialei, HUA Mingtao. Reversal effect and mechanism of polyene phosphatidylcholine on oxaliplatin resistance of gastric cancer cells in a nude mouse model [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 385-390.
[9]	SUN Zugang,WANG Zhe,CHEN Huaian,LIU Shuo,MIAO Wenlong. Progress in common chronic inflammatory factors inducing bladder cancer and its immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 357-361.
[10]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[11]	YAO Qiang, WANG Kuan, XUE Yingwei. Expression of SRC1 in gastric cancer and its prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 97-102.
[12]	YU Jiahui, LIU Xuan, LI Qi, LU Ye, YUE Xiaoqiang. Regulative mechanism of long non-coding RNA in gastric cancer and its role in traditional Chinese medicine [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 47-52.
[13]	LIU Guohui, GU Anxin, YIN Hongtao, CAO Yang, HE Yunlong, WANG Chunbo, E Mingyan. Protosappanin A increases the sensitivity of gastric cancer SGC-7901 cells to radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 500-505.
[14]	ZHANG Chunhui, LIU Xia, XU Jingjing, ZHOU Yanhua, ZHAO Juan, LI Zhiwei, ZHANG Yanqiao. Clinicopathological features and survival analysis in 633 cases of gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 396-404.
[15]	SUN Lina, ZHAO Xiaodi, LU Yuanyuan, WANG Xin. Research progress of LncRNA and chemotherapy resistance in gastrointestinal neoplasms [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 448-453.

Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments